Short Report
Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia
Author affiliations
1 Addis Ababa University, College of Health Science, School of Medical Laboratory Sciences, Addis Ababa, Ethiopia
2 St. Peter’s TB Specialized Hospital, Addis Ababa, Ethiopia
3 Addis Ababa University, College of Health Science, School of Public health, Addis Ababa, Ethiopia
4 Department of Epidemiology and Biostatistics, Jimma University, College of Public Health and Medical Science, Jimma, Ethiopia
Citation and License
BMC Research Notes 2012, 5:462 doi:10.1186/1756-0500-5-462
Published: 28 August 2012Abstract
Background
Drug-resistant TB has emerged as a major challenge facing TB prevention and control efforts. In Ethiopia, the extent/trend of drug resistance TB is not well known. The aim of this study was to determine the pattern and trend of resistance to first line anti-TB drugs among culture positive retreatment cases at St.Peter’s TB Specialized Hospital.
Findings
A hospital based retrospective study was used to assess the pattern of anti-TB drug resistance among previously treated TB patients referred to St.Peter’s TB Specialized Hospital from January 2004-December 2008 Gregorian calendar(GC) for better diagnosis and treatment.
Among 376 culture positive for M. tuberculosis one hundred and two (27.1%) were susceptible to all of the four first line anti-TB drugs -Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETB) & Streptomycin (STM). While 274 (72.9%) were resistant to at least one drug. Any resistance to STM (67.3%) was found to be the most common and the prevalence of MDR-TB was 174 (46.3%). Trend in resistance rate among re-treatment cases from 2004 to 2008 showed a significant increase for any drug as well as for INH, RIF, and MDR resistance (P <0.05 for trend).
Conclusions
There has been an increasing trend in drug resistance in recent years, particularly in retreatment cases. Therefore, establishing advanced diagnostic facilities for early detection of MDR-TB and expanding second line treatment center to treat MDR-TB patients and to prevent its transmission is recommended.
